Onxeo

Report Publication Announcement • Feb 17, 2016

Onxeo to attend upcoming investor conferences and medical meetings

Paris (France), Copenhagen (Denmark), February 17, 2016 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that senior management will present updates on the Company's advanced orphan oncology pipeline at the following upcoming investor conferences:

• ODDO Biotech / Medtech Forum March 31, 2016 in Paris (France)
• SFAF Journée Sectorielle Biotech May 15, 2016 in Paris (France)
• Jefferies Healthcare Conference June 7-10, 2016 in New York (U.S.A)
• European Large and Midcap Event October 5-6, 2016 in Paris (France)

In addition, Onxeo will present at the following medical meetings:

• EASL, The International Liver Congress April 13-17, 2016 in Barcelona (Spain)
• AACR Annual Meeting 2016 April 16-20, 2016 in New Orleans (U.S.A)
• ESTRO Annual Meeting 2016 April 29-May 3, 2016 in Turin (Italy)

Onxeo's next financial updates will be released on the following dates:

• Full-Year 2015 Results February 26, 2016 (after the close of market)
• Full-Year 2015 Results and Company Update Analyst Conference Call February 29, 2016 (6:30 PM CET; dial-in details to be released beforehand)
• Annual SFAF Meeting March 7, 2016 (11:00 AM CET) in Paris (France)

Investors and analysts interested in scheduling a meeting with Onxeo management or participating in a Company conference call can contact Onxeo's Investor Relations team (investors@onxeo.com) or Lee Roth and Joseph Green at The Ruth Group (+1 646-536-7012/7013 or lroth@theruthgroup.com / jgreen@theruthgroup.com).

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on developing innovative therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo's first approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully developed and registered two non-cancer products which are currently being commercialized in the U.S. and Europe. Onxeo's vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective, and safe therapeutics designed to improve the lives of patients. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and NASDAQ Copenhagen, Denmark (Ticker: ONXEO).

Onxeo orphan oncology products at the advanced development stage are:

• Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
• Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis;
• Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency's accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo's partner in the U.S., Spectrum Pharmaceuticals; belinostat in combination with CHOP (BelCHOP) is also in development as first-line treatment for patients with PTCL.

For more information, visit the website www.onxeo.com

To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/ Follow us on Twitter: @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).

Contact:

Nathalie Delair-Trepo Investor Relations, Onxeo investors@onxeo.com + 33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie – Alize RP (France) onxeo@alizerp.com +33 6 64 18 99 59 / +33 6 47 38 90 04

Kirsten Thomas / Lee Roth – The Ruth Group (U.S.) kthomas@theruthgroup.com / lroth@theruthgroup.com +1 508 280 6592 / +1 646 536 7012